First FDA-Approved Plant-Based Drug "Cytisinicline" Helps Smokers Quit E-Cigarettes

Innovation by 2FIRSTS.ai
May.07.2024
First FDA-Approved Plant-Based Drug "Cytisinicline" Helps Smokers Quit E-Cigarettes
Massachusetts General Hospital researchers have developed a plant-derived drug to help smokers quit e-cigarettes, awaiting FDA approval.

According to a report by JAMA Internal Medicine on May 6th, researchers at Massachusetts General Hospital in the United States have developed the first drug to help smokers quit e-cigarettes, a plant-based medication called "Cytisinicline". It is currently on track to receive approval from the US Food and Drug Administration (FDA).

 

A new study published in the Journal of the American Medical Association (JAMA Internal Medicine) has shown that a drug developed by a general hospital in Massachusetts, called Golden Thistle Alkaloid, has significant potential in aiding smoking cessation. The drug is expected to receive full approval from the FDA and become the first medication approved for helping individuals quit e-cigarettes. The co-authors of the study report that approximately 11 million American adults use e-cigarettes containing nicotine, with about half expressing a desire to quit smoking.

 

According to a new study, a double-blind randomized clinical trial involving 160 e-cigarette users who did not use traditional tobacco was conducted. During the 12-week trial, they were either given cytisine tablets or a harmless placebo. The results showed that those treated with cytisine were more likely to quit smoking by the ninth week compared to those taking the placebo (31.8% vs. 15.1%). The research team also found that there were very few, if any, side effects for participants who took cytisine tablets.

 

Nancy A. Rigotti, MD, director of the Tobacco Research and Treatment Center at Massachusetts General Hospital and professor of medicine at Harvard Medical School, stated, "In the United States, no medication has been approved for quitting e-cigarettes yet, and our research suggests that varenicline could fill this gap and help adults quit using e-cigarettes."

 

The magic of lobeline lies in its ability to bind with nicotine receptors in the brain cells of smokers, making it a promising medication for both smokers and e-cigarette users. While lobeline is seen as a hopeful treatment for tobacco and e-cigarette cessation, it will still require some time to receive full approval from the FDA.

 

During this process, many drugs ultimately fail to withstand the full course of testing. It is estimated that out of every 5000 to 10000 compounds that enter preclinical trials, only one eventually receives approval for use in patients.

 

In the development process, drugs need to go through many steps before they can reach the hands of patients. The development of new drugs or vaccines is a complex and rigorous process that may take several years. This process is conducted under strict regulation to ensure the safety and effectiveness of the medication. It includes various stages such as preclinical trials, Investigational New Drug (IND) studies, and clinical trials, before the drug can be prescribed by doctors to patients after FDA approval.

 

Notice

1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.

2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.

3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.

Copyright

This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.

This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.

Russian NGO Calls for Halt of 2025 E-cigarette Expo, Citing Illegal Promotion of Nicotine Products
Russian NGO Calls for Halt of 2025 E-cigarette Expo, Citing Illegal Promotion of Nicotine Products
The Russian social movement organization "Сорок Сороков" has filed complaints with the prosecutors' offices in Moscow and Novosibirsk, demanding the ban of the 2025 E-cigarette Expo (Vape Club Show). The complainants argue that the event constitutes illegal promotion of nicotine products and sets a bad example for young people.
May.07 by 2FIRSTS.ai
PMI Plans Expansion of New Tobacco Products in Philippines
PMI Plans Expansion of New Tobacco Products in Philippines
PMI plans to introduce more tobacco products in the Philippines, confident in success based on Manila experience.
Apr.08 by 2FIRSTS.ai
Smoore Announces Equity Incentive Plan: Grants Over 4M Shares to 49 Employees, Valued at Over HK$54.14M
Smoore Announces Equity Incentive Plan: Grants Over 4M Shares to 49 Employees, Valued at Over HK$54.14M
Smoore International has granted a total of 4.004 million shares to 49 employees under its share award and option plans. The package includes 1.614 million awarded shares and 2.39 million options exercisable at HK$13.52 per share, with a total value of HK$54.14 million.
May.08 by 2FIRSTS.ai
Antitrust Lawsuit: Redbud Roots Inc. vs. Smoore and Others
Antitrust Lawsuit: Redbud Roots Inc. vs. Smoore and Others
US Redbud Roots Inc. files anti-monopoly lawsuit against Smoore and other companies, alleging price manipulation and competitive suppression.
Apr.15 by 2FIRSTS.ai
With Illegal E-Cigs Dominating 90% Market, Can American Democrats and Republicans Jointly 'End' the Gray Zone?
With Illegal E-Cigs Dominating 90% Market, Can American Democrats and Republicans Jointly 'End' the Gray Zone?
US House Oversight Committee Holds Hearing on Restoring Trust in FDA, Addressing Illicit Products; Controversy Surrounds Approval Process.
Apr.22 by 2FIRSTS.ai
Random Inspection Implementation Plan for Certified E-cigarette Enterprises
Random Inspection Implementation Plan for Certified E-cigarette Enterprises
Strict random checks are being implemented by certified e-cigarette companies to adhere to government regulations and ensure industry compliance.
Mar.24 by 2FIRSTS.ai